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Abstract
Background & Aims: The addition of protease inhibitors, boceprevir (BOC) or telaprevir (TRV), to peg-interferon and ribavi-
rin (PR) increases the incidence of anaemia in patients with chronic hepatitis C virus (HCV) infection. Although genetic vari-
ants in inosine triphosphatase (ITPA) gene have been linked to the haemolytic anaemia induced by PR, the mechanism
sustaining severe anaemia during triple therapy is still unknown. This study aims to elucidate the molecular mechanisms
underlying anaemia in chronic HCV patients with combined therapy. Methods: We studied 59 patients with chronic HCV
genotype-1: 29 treated with TRV/PR and 30 with BOC/PR. We evaluated biochemical and haematological parameters, red
cell index at baseline, 4, 12, 16 and 24 weeks of treatment; in a subgroup, we performed functional studies: osmotic fragil-
ity, red cell membrane protein separation, mass spectrometry analysis, quantification of erythroid microparticles release.
IL28B and ITPA polymorphisms were also evaluated. Results: We found early acute normochromic normocytic haemolytic
anaemia (4–8 weeks) followed by a late macrocytic hypo-regenerative anaemia with inappropriate low reticulocyte count
(12–24 weeks). Studies on red cells revealed: (i) presence of spherocytes; (ii) increased osmotic fragility; (iii) abnormalities in
red cell membrane protein composition; (iv) reduced membrane-cytoskeleton stability; (v) increased release of erythroid mi-
croparticles. ITPA polymorphisms impacted only the early phase of anaemia. Conclusions: The bimodal pattern of anaemia
in chronic HCV patients on triple therapy might be because of acquired spherocytic-like anaemia in the early phase, followed
by hyporegenerative anaemia, most likely related to the combined effects of PR and TRV or BOC on erythropoiesis.
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About 170 million individuals worldwide have chronic
hepatitis C virus (HCV) infection, accounting for about
one-third of all cases of chronic viral hepatitis (1). More
than 350 million people die each year from complica-
tions of HCV-related cirrhosis and hepatocellular carci-
noma (WHO 2013). Treatments for chronic HCV
infection are evolving.
Individuals infected with HCV genotype-1 (HCV-1)
have been considered the most difficult to treat and
since 2011 the standard of care for HCV-1 is triple ther-
apy with pegylated-interferon-alpha (peg-IFNa) and
ribavirin (RBV) (PR) plus one of the two-first-wave,
first-generation protease inhibitors (PIs), telaprevir
(TVR) and boceprevir (BOC). Sustained virological
response, defined as undetectable HCV-RNA in serum
24 weeks after the end of treatment, is achieved in
approximately 70% of cases (2). However, the addition
of PIs to PR worsened side effects, with anaemia being
one of the most serious one (3, 4), particularly in
cirrhotic patients (5).
Previous studies showed that anaemia induced by
RBV is mainly related to red blood cells (RBC) mem-
brane oxidation resulting in increased erythrophago-
cytic extravascular removal (6). This is also associated
with a bone marrow suppression component medi-
ated by peg-IFNa and RBV actions (7). The severity
of PR-induced anaemia is further increased by BOC
or TVR, through a still unknown mechanism(s). A
genome wide association study has identified single
nucleotide polymorphisms (SNPs) within inosine tri-
phosphatase (ITPA) gene as being significantly associ-
ated with RBV-induced anaemia (8, 9), suggesting
ITPA-SNPs as useful marker to predict the degree of
anaemia in HCV patients receiving triple therapy
(10). However, the recent revision of data from two
large cohorts of triple-treated patients has underlined
that the higher incidence of severe anaemia is not
only associated to ITPA genetic variants, but addi-
tional still unknown mechanisms should also contrib-
ute to it (11).
Since 2014, new direct-acting antivirals have been
licensed in the USA and EU for use as part of combina-
tion therapy for HCV infection, with better tolerability
(2, 12, 13). However, these molecules are costly and this
represents in several countries a major limitation in the
access to treatment for many patients, particularly for
those with a lower degree of liver fibrosis. For this rea-
sons, the antiviral scheme employing the combination
of PR, with or without first- or second-generation PIs, is
expected to be used much longer.
The aims of this study are to assess type of anaemia
in chronic HCV patients treated with either TVR or
BOC to disentangle the mechanisms of anaemia because
of anti-HCV present treatment.
Patients and methods
Patients and study design
We enrolled 59 chronic HCV-1 patients treated with
TVR (n = 29) or BOC (n = 30). For inclusion and
exclusion criteria see Supplementary material. Patients
were examined at baseline, week 4 (end of PR lead-in
phase), and 12 (8 weeks of PI + PR). Patients receiving
TVR triple therapy were examined at week 16 (end of
12 weeks of PR/TVR), and those receiving BOC triple
therapy at week 24 (20 weeks of PR/BOC) (Fig. S1).
Informed consent was obtained by all enrolled patients
according to Declaration of Helsinki and principles of
Good Clinical Practice. This study protocol was
approved by the ethics committees of the AOUI-
Verona, University of Verona and University of Udine.
Anaemia definition, haematological parameters and RBC
osmotic fragility assay
Anaemia (Hb<10 g/dl) and severe anaemia (Hb<8.5 g/
dl) were defined at any time during treatment. Early
anaemia corresponded to Hb<10 g/dl during the first
4 weeks of treatment. Osmotic fragility curves were
evaluated after blood sampling (0 h) and at 24 h incu-
bation at room temperature (14–16).
ITPA genotypes and predicted activity
ITPA-SNPs rs1127354 and rs7270101 genotyping was
performed by direct sequencing, and the predicted ITPA
activity was estimated as described (8). See Supplemen-
tary material.
Key points
• In chronic HCV patients, triple therapy induced a
bimodal pattern of anaemia, which is characterized
by an early acquired spherocytic-like anaemia, wors-
ened by an inappropriate low reticulocyte count.
• The hyporegenerative anaemia appears in late
phase of triple therapy, most likely related to com-
bine effects of PR and TRV of BOC on erythropoie-
sis.
• ITPA polymorphisms impact only the early phase
of anaemia but not its degree.
• Functional studies of red cells from chronic HCV
patients during triple therapy revealed changes in
membrane protein composition, reduced red cell
membrane mechanical stability and increased release
of erythroid microparticles.
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Red cell membrane protein separation, immune-blot and
mass-spectrometric analyses
A subgroup of 21 patients (TRV, n = 9; BOC, n = 12)
underwent functional studies. RBC membrane proteins
were prepared and separated on SDS-PAGE. Gels were
either stained with colloidal Coomassie or transferred to
nitrocellulose membrane for immunoblot analysis (17–
20). Image analysis was performed by Image Quant Las
Mini 4000 Digital Imaging System (GE Healthcare Life
Sciences, Little Chalfont, UK), and densitometric analy-
sis by ImageQuant TL software (GE Healthcare Life Sci-
ences) (20–22). Bands differently expressed in colloidal
Coomassie-stained gels were used for mass spectrometry
(MS) (19, 23, 24). MS was performed using a Tofspec
SE (Micromass, Manchester, UK). See Supplementary
material.
Erythroid microparticles
Erythroid microparticles (MPs) were isolated from
plasma of patients and healthy subjects as reported (25,
26). See Supporting information.
Statistical analysis
Median, mean, range and SD were used as descriptive
statistics. The differences between the two treatment
groups and demographical, clinical and pathological
features at baseline were tested using non-parameters
methods for continuous variables and chi squares and
exact test for dichotomous variables, as appropriate. P
value <0.05 was considered significant in two-tailed
tests. All the computations were carried out using the
STATA program version 12.0 (STATA Statistics/Data Analy-
sis 12.0 – STATA Corporation, College Station, TX,
USA). See Supporting information.
Results
Patient characteristics
The baseline characteristics of the patients are shown in
Table 1. Median age was 55 years and 72.9% were
males. Forty-three (72.9%) patients had clinical or his-
tological compensated cirrhosis in Child-Pugh class A.
Upper gastrointestinal endoscopy was performed before
Table 1. Baseline characteristics of the patients
Characteristics Telaprevir (n = 29) Boceprevir (n = 30) Overall (n = 59)
Age (years) 53.4 (39.8–73.9) 56.8 (41.3–70.6) 55.7 (39.8–73.9)
Male gender 21 (72.4) 22 (73.3) 43 (72.9)
METAVIR F3/F4 (n = 46) 19 (82.6) 18 (78.3) 37 (80.4)
Cirrhosis* 23 (79.3) 20 (66.7) 43 (72.9)
Oesophageal varices 5 (17.2) 3 (10.0) 8 (13.6)
Splenomegaly† 19 (65.5) 14 (46.7) 33 (55.9)
Treatment history
Naive 6 (20.7) 5 (16.7) 11 (18.6)
Prior relapse 10 (34.5) 5 (16.7) 15 (25.4)
Prior partial response 3 (10.3) 7 (23.3) 10 (17.0)
Prior null response 6 (20.7) 9 (30.0) 15 (23.4)
Undetermined 4 (13.8) 4 (13.3) 8 (13.6)
ALT (IU/L) 92 (17–289) 75 (22–572) 81 (17–572)
AST/ALT ratio 0.76 (0.42–1.12) 0.71 (0.47–1.33) 0.76 (0.42–1.33)
Albumin (g/L) 41.5 (33.3–47.9) 42.5 (34.5–49.2) 41.8 (33.3–49.2)
MCV (fL) 90.6 (80.6–98.9) 90.5 (80.1–97.7) 90.5 (80.1–98.9)
Hb (g/dl) 15.0 (11.3–16.9) 15.3 (13–17.3) 15.2 (11.3–17.3)
Platelets (109/L) 146 (74–282) 149 (88–290) 149 (74–290)
Creatinine (mg/dl) 0.80 (0.55–1.18) 0.83 (0.62–1.16) 0.81 (0.55–1.18)
IL28B rs12979860
CC/CT/TT
6/22/1 5/19/3 11/41/4
ITPA rs1127354
CC/CA/AA
21/7/0 26/4/0 47/11/0
ITPA rs7270101
AA/AC/CC
23/4/1 25/5/0 48/9/1
Data are expressed as median (range) or number (%).
*histological and/or clinical cirrhosis defined by ultrasonography features suggestive of cirrhosis based on a quantitative scoring system derived from
the appearance of the liver margins, parenchymal echotexture, portal vein calibre and spleen diameter, supplemented with the presence of oesopha-
geal varices.
†longitudinal diameter >10 cm on abdominal ultrasound.
P > 0.05 for each comparison of distributions or proportions between Telaprevir and Boceprevir using Mann–Witney test for unpaired data and chi-
squared or exact test.
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therapy in all cirrhotic patients and eight of them had
oesophageal varices. All patients had abdomen ultra-
sound performed at baseline and splenomegaly was
present in 33 of them, including 26 cirrhotics. Twenty-
nine patients received triple therapy with TVR and 30
with BOC. The demographical and clinical characteris-
tics were similar between TVR and BOC groups
(P > 0.05 for each variable).
BOC or TVR triple therapy induced a bimodal anaemia
Anaemia and severe anaemia were observed in 9
(30.0%) and 1 (3.3%) patients in the BOC group and in
14 (48.3%) and 1 (3.4%) patients in the TVR group. In
the BOC group, 12 (40.0%) reduced RBV dose, 5
(16.7%) reduced RBV dose and received either EPO or
transfusion; in the TVR group, 12 (41.4%) reduced RBV
dose, 1 (3.4%) received EPO, and 8 (34.5%) required
combined measures. Hb levels decreased rapidly from
baseline to 4 and 12 weeks of treatment, and then
remained stable at 16 or 24 weeks of therapy with TVR
or BOC respectively (Table S1, Fig. 1A). The decrease in
Hb levels (TVR group, 15.0–10.5 g/dl; BOC group,
15.3–10.6 g/dl) was similar in both groups (P > 0.05).
The mean cell volume (MCV) was stable in both groups
between 0 and 4 weeks, and increased afterwards. Con-
sequently, the mean cell haemoglobin (MCH) signifi-
cantly decreased from the baseline to 4 week
(P < 0.001) and then increased at 12, 16, and 24 weeks
of treatment in both groups (P < 0.001). The RBC dis-
tribution width (RDW) significantly increased up to
12 weeks, followed by a significant decreased afterwards
in both groups (P < 0.05 for each comparison).
The time trend of these haematological parameters
from the baseline to 4, 12, 16 and 24 weeks was statis-
tically significant using mixed linear regression models
with a spline term for time as independent variable
(P < 0.001 for each parameter) without differences
between the two groups. The differences between base-
line and at 16 and 24 weeks values were statistically
significant for all parameters when also including in
the model group, presence of cirrhosis and spleno-
megaly as independent variables. A similar time effect
of TVR/BOC-PR combination therapy on RBC indices
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Fig. 1. Haematological parameters in triple-treated HCV patients. (A) Haematological parameters during triple therapy. (B–C) Distribution of
RBC indices according to predicted ITPA activity during triple therapy. Data are presented as mean ± SD. *P ≤ 0.01.
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was observed in the subgroup of 21 patients analysed
for functional studies (Table S2). Reticulocytes
response was significantly different between the two
groups at 4 weeks (no baseline measure was available)
and it showed a significant decrease after BOC therapy
from 4 to 24 weeks and no change in TVR group. It
is of interest to note a lacking in reticulocyte response
to the degree of anaemia in both TRV and BOC
(Table S2).
ITPA polymorphism and pattern of anaemia in chronic
HCV patients undergoing triple therapy
We evaluated protective ITPA-SNPs rs1127354 and
rs7270101 for anaemia. Both polymorphisms were in
Hardy–Weinberg equilibrium (P > 0.05) (Table 1). No
differences in the minor allele frequencies of the two
SNPs between control Italian population TSI (n = 98)
and HCV patients (n = 58) were observed (A: 0.11/0.09,
rs1127354; T: 0.10/0.09, rs7270101; P > 0.05 for each
comparison). No significant differences were found
comparing the two treatment groups.
We divided our cohort in two subgroups, according
to the predicted ITPA activity on the basis of ITPA-
SNPs: (i) patients with normal/intermediate enzymatic
activity (60–100%, n = 46) and (ii) patients with low/
very low activity (0–30%, n = 12). Patients with
0–30%-ITPA activity showed a higher Hb level after
4 weeks of treatment with either TRV (13.4 ± 0.5 g/dl)
or BOC (13.6 ± 0.5 g/dl) compared to patients with
60–100%-ITPA activity (TRV, 11.9 ± 0.3 g/dl; BOC,
12.5 ± 0.2 g/dl) (P = 0.01) (Fig. 1B,C). However, both
groups reached the same Hb level after 12 weeks of
treatment (Fig. 1C).
At 12 weeks, patients with 60–100%-ITPA activity
exhibited a markedly increased MCV (TRV,
97.1 ± 1.6 fl; BOC, 99.1 ± 1.3 fl) compared to those
with 0–30%-ITPA activity (TRV, 92.2 ± 1.0 fl; BOC,
93.5 ± 1.8 fl) (P = 0.01) (Fig. 1B,C). Similarly, a ten-
dency to increase MCH and RDW in 60–100% patients
(MCH: TRV, 31.6 ± 0.4 pg; BOC, 31.5 ± 0.4 pg –
RDW: TRV, 15.0 ± 0.3%; BOC, 16.0 ± 0.3%) com-
pared to 0–30% patients (MCH: TRV, 30.6 ± 0.5 pg;
BOC, 30.4 ± 0.8 pg – RDW: TRV, 14.2 ± 0.4%; BOC,
15.8 ± 0.4%) was observed after 12 weeks of treatment,
although not significant (Fig. 1B,C).
Spherocytosis-like anaemia in the early phase of treatment
Functional studies on RBC showed the presence of
micro and macrospherocytes at 4, 8, 12 and 16 weeks of
treatment with either BOC or TRV (Fig. 2A). Both
direct and indirect agglutination tests for immune-med-
iated haemolytic anaemia were negative. At baseline, the
osmotic fragility curves at 0 and 24 h were similar to
those observed in healthy controls (data not shown).
After 4, 8, 12 and 16 weeks of treatment, an increased
osmotic fragility at 24 h after blood sampling was
observed, as indicated by the appearance of haemolysis
at 156 mOsm point. This was more marked in TVR-
treated patients at 8 weeks of therapy compared to BOC
ones (Fig. 2B).
The analysis of RBC membrane proteins showed no
major protein defects in patients at baseline (Fig. 3A).
In BOC group a significant reduction compared to base-
line in a-spectrin (8 weeks: 66.6 ± 2.5%, 12 weeks:
65 ± 4.3%, n = 12; P < 0.05), b-spectrin (8 weeks:
67 ± 1.1%, 12 weeks: 71 ± 2.2%, n = 12; P < 0.05) and
in band 4.2 (8 weeks: 55.2 ± 3.9%, 12 weeks:
58 ± 4.1%, n = 12; P < 0.05) was observed. Similarly,
in TRV group we found a significant reduction com-
pared to baseline in a-spectrin (8 weeks: 78 ± 3%,
12 weeks: 69 ± 2.8%, n = 9; P < 0.05), b-spectrin
(8 weeks:73 ± 3.4%, 12 weeks: 66 ± 4.7%, n = 9;
P < 0.05) and in ankyrin (12 weeks: 52 ± 1.2%,
16 weeks: 61 ± 1.7%, n = 9; P < 0.05) (Fig. 3A). The
identification of these proteins was then validated by
MS (data not shown). The image analysis of the gels
revealed also the appearance of addition bands in the
molecular range between 135 kDa and 245 kDa
(Fig. 3A). These bands were numbered from 1 to 7 and
1 to 6 in RBC from, respectively, BOC and TRV groups
and identified by MS. We found fragments of ankyrin
(band 1, 2, 4, 7 in BOC and band 2, 3, 5 in TRV) and
membrane associated small GTPase (band 3, 5, 6 in
BOC and band 1, 4 in TRV) (Table S3). The level of b-
adducin Ser-726 phosphorylation was significantly
increased in a time dependent fashion in both groups
compared to baseline levels (Fig. 3B). The levels of b-
adducin phosphorylation in TRV group were higher
compared to BOC group, suggesting a more severe cyto-
skeleton instability of RBC from TRV-treated patients
than BOC ones (Fig. 3B).
Release of erythroid microparticles after 8 weeks of triple
therapy
We evaluated the release of erythroid MPs in plasma
samples from triple-treated patients at baseline and at
the different time points. We did not find significant
differences in erythroid MPs from chronic HCV patients
compared to healthy controls at baseline (data not
shown). Nevertheless, at 8 weeks of treatment we found
significant increased amount of erythroid MPs in both
BOC and TRV groups compared to healthy controls
(Fig. 3C), indicating a disruption in membrane-skeleton
network related to triple therapy.
Discussion
Here, we found a bimodal profile of anaemia in HCV
patients undergoing triple therapy, characterized by an
early phase with acute haemolytic spherocytosis-like
anaemia, corresponding to the first 8 weeks of treat-
ment, followed by the appearance of a hyporegenerative
component at 12 weeks of treatment, which is
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responsible for the lacking bone marrow response. We
did not observe differences in the degree of anaemia
between BOC- and TRV-treated subjects, in agreement
with previous reports (3). The drop in Hb levels was sig-
nificant at 4 weeks of treatment and was higher in
patients with normal ITPA activity compared to subjects
with reduced ITPA activity. The RBC indices showed
the bimodal change characterized by normochromic
normocytic anaemia in the early phase of treatment (0–
4–8 weeks) followed by macrocytic anaemia with a sig-
nificant increase in MCV and MCH values at 12 weeks
of treatment, through the end of the therapy. Of note,
patients carrying ITPA-SNPs genotype associated to a
reduced enzymatic activity exhibited lower MCV and
MCH values compared to subjects with normal activity.
Nevertheless, all patients result in a comparable degree
of anaemia after 12 weeks of treatment, regardless of
ITPA activity. Thus, ITPA-SNPs could contribute to
explain at least partly the inter-individual variability in
early phase of anaemia in the response to triple therapy
(27). Our data suggest that anaemia in triple-treated
patients results by a combination of different factors
synergizing on anaemia. In fact, during PIs combine
therapy, we observe the appearance of micro and mac-
rospherocytes, which was associated with increased
osmotic fragility, with negative direct/indirect agglutina-
tion tests. Of note, the increased osmotic fragility was
more severe in TVR-treated patients than in BOC ones.
This might be related to the differences in the ability to
cross the cell membranes (28–30). Since erythrocytes
survive in the peripheral circulation 120 days, con-
trolled proteolysis of RBC membrane-cytoskeletal pro-
teins is required in membrane-cytoskeletal remodelling
(31). Thus, in RBC from triple-treated patients some
changes in protease function combined with oxidative
stress may affect the machinery involved in membrane-
cytoskeletal stability, in agreement with previous reports
(32). This is supported by the reduction in a- and b-
spectrins from 4–8 weeks to 12–16 weeks of treatment,
indicating a spherocytic-like morphological change.
Indeed, reductions of these proteins are linked to hered-
itary spherocytosis (33). In PIs treated patients, the
(A)
(B)
Fig. 2. Morphological and biochemical parameters in triple-treated HCV patients. (A) RBC morphology from patients at baseline and after
BOC/TRV treatment. Blood smears were stained with May-Grunwald-Giemsa. One representative image from 9 BOC- and 12 TRV-patients.
(B) Osmotic fragility curves of RBC at 0 and 24 h after blood withdrawal; *increased osmotic fragility at 156 mOsm. One representative
image from 9 BOC- and 12 TRV-patients for each time points. The charts show the red cell lysis % at 156 mOsm in treated patients.
*P < 0.05; **P < 0.05; ***P < 0.001.
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detection of additional bands between 135 and 240 kDa,
identified as ankyrin, might result from either alterna-
tive splicing or inhibition of controlled proteolytic
cleavage of ankyrin, which is involved in maturation of
erythrocyte in the peripheral circulation (34). MS also
revealed the presence of small GTPase proteins associ-
ated to the RBC membrane from 8 weeks-treated
patients. In red cells, small GTPases have been related to
events involved in the dynamic association of the mem-
brane-skeleton network, which parallel changes in phos-
phorylation state of b-adducin (35, 36). Changes in
phospho-b-adducin results in disruption of actin-spec-
trin association, affecting cytoskeleton remodelling (37–
39). A time dependent increased in red cell b-adducin
phosphorylation was observed, supporting the perturba-
tion in dynamic regulation of cytoskeletal network
induced by the combined therapy. Overall, these data
indicate that both BOC and TRV promote acute
acquired spherocytic-like anaemia in the early phase of
the treatment as supported by (i) the presence of
spherocytes; (ii) the increase osmotic fragility at 24 h;
(iii) the changes in red cell membrane composition; and
(iv) the increased in phosphorylation of b-adducin.
Previous reports on hereditary spherocytosis have
shown that the instability between membrane and cyto-
skeleton network promotes erythroid vesiculation slugg-
ishing in microcirculation with release of MPs. This
results in abnormal RBC volume/surface ratio and gen-
eration of spherocytes (40). Accordingly, we found a
significant increase in erythroid MPs in both BOC- and
TRV-treated subjects at 8 weeks of treatment.
One of the major effects of the presence of sphero-
cytes owing to reduced survival is the increased reticulo-
cyte count in response to anaemia through EPO
stimulation. However, in these patients, we did not find
the expected increase in reticulocyte count, following
the drop in Hb levels, suggesting a failure in erythropoi-
esis during triple therapy at 8–12 weeks of treatment.
This is also supported by the increase in MCV values
observed in other disorders characterized by dyserythro-
poiesis such as Congenital Dyserythropoietic Anaemias
(41). The lack of erythropoietic response might be
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related to the combination of PR effects on erythroid
precursors (7), synergizing with BOC and TRV.
This is the first functional study, which aims to unra-
vel the characteristics of anaemia induced by triple ther-
apy for chronic HCV patients. The main weakness of
this study is the small number of patients recruited for
functional studies, because of requirement of fresh
blood to be immediately processed within few hours
after sampling. However, the patients were enrolled
consecutively among those undergoing triple therapy in
Hepatology Centres according to the current guidelines
for treatment of chronic HCV patients in routine activ-
ity and therefore they can be considered representative
of all those treated according to present anti-HCV sche-
dule.
We believe that our results may still be of interest
in the era of new antiviral drugs. The treatment of
HCV chronic hepatitis has evolved rapidly, starting
with the availability of first generation PIs (2). These
drugs are allowed to treat HCV-1-infected patients
who had failed PR dual therapy. Subsequently the
scheme based on the use of triple therapy with sof-
osbuvir and PR made possible to shorten the treat-
ment, improving its tolerability. Currently, several
new drugs besides sofosbuvir are available for the
treatment of chronic HCV hepatitis, including sec-
ond-generation PIs (13, 42). Despite the advantage in
the efficacy and tolerability, the access to treatment
with new antivirals is limited by their high cost (43).
In several industrialized countries, the access to treat-
ment with new antivirals is reserved only to patients
with cirrhosis or severe liver fibrosis while in less
advanced stages of liver disease antiviral therapy with
PR and first- or second-generation PIs is still cur-
rently adopted. In countries where the access to new
antivirals will remain to be available only for patients
with more advanced liver disease, seem justifiable to
consider antiviral schemes based on IFN combina-
tions to eradicate HCV infection in patients with less
severe liver disease before the progression to cirrhosis.
In addition, the possibility that new generation anti-
HCV PIs might induce abnormalities in erythrocyte
structure similar to those here described, even when
used in IFN-free regimens with RBV, cannot be
excluded and will deserve to be evaluated in future
studies.
In conclusion, we propose a bimodal anaemia in
chronic HCV patients treated with combined therapy:
an early acute haemolytic acquired spherocytic-like
anaemia (4–8 weeks), which subsequently is sustained
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Fig. 4. Bimodal anaemia in triple-treated HCV patients. Protein components of erythrocyte membrane and cytoskeleton in physiological
conditions. The combined therapy results in acquired spherocytic-like anaemia in the early phase: spherocytic RBC with increased vesicula-
tion; reduction in a- and b-spectrins (thin lines); increased b-adducin phosphorylation and proteolytic cleavage of ankyrin (dotted line). An
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by an impairment of erythropoiesis (8–12 weeks to the
end of the treatment) (Fig. 4).
Future studies should be carried out to better define
the effects of first- or second-generation PIs combined
with PR on erythropoiesis to improve the haematologi-
cal outcome of chronic HCV patients undergoing triple
therapy.
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